Equity research analysts expect Sotera Health (NYSE:SHC – Get Rating) to report sales of $230.05 million for the current quarter, according to Zacks Investment Research. Three analysts have released earnings estimates for Sotera Health, with the lowest sales estimate at $227.30 million and the highest estimate at $232.46 million. Sotera Health reported sales of $212.15 million in the same quarter last year, indicating a positive year-over-year growth rate of 8.4%. The company is expected to release its next results before the market opens on Monday, January 1.
On average, analysts expect Sotera Health to report annual revenue of $1.02 billion for the current fiscal year, with estimates ranging from $1.01 billion to $1.02 billion. For the next fiscal year, analysts expect the company to post sales of $1.11 billion, with estimates ranging from $1.09 billion to $1.12 billion. Zacks sales calculations are an average average based on a survey of research analysts who track Sotera Health.
Sotera Health (NYSE:SHC – Get Rating) last released its results on Tuesday, March 1. The company reported earnings per share (EPS) of $0.22 for the quarter, beating analyst consensus estimates of $0.21 by $0.01. The company posted revenue of $241.25 million in the quarter, compared to $238.90 million expected by analysts. Sotera Health had a net margin of 12.55% and a return on equity of 42.00%. Sotera Health’s quarterly revenue increased 11.3% compared to the same quarter last year. In the same quarter last year, the company posted EPS of $0.07.
Several brokerages have weighed in on SHC. Barclays cut Sotera Health shares from an “overweight” rating to an “equal weight” rating and set a price target of $24.00 for the company. in a research note from Wednesday, March 2. Goldman Sachs Group lowered its price target on Sotera Health shares from $31.00 to $27.00 and set a “buy” rating for the company in a Monday, March 21 research note. Jefferies Financial Group cut Sotera Health shares from a “buy” to a “hold” rating and lowered its price target for the stock from $34.00 to $22.00 in a research note from the Thursday, March 3. Zacks Investment Research upgraded Sotera Health shares from a “hold” rating to a “strong sell” rating in a Wednesday, March 9 research note. Finally, Credit Suisse Group lowered its price target on Sotera Health shares from $31.00 to $28.00 and set an “outperform” rating on the stock in a Wednesday, March 2 report. One financial analyst has assigned the stock a sell rating, two have assigned a hold rating and four have assigned the stock a buy rating. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $26.57.
Sotera Health shares opened at $20.38 on Friday. Sotera Health has a 12-month low of $18.31 and a 12-month high of $27.38. The company has a quick ratio of 1.81, a current ratio of 2.15 and a debt ratio of 3.04. The company has a 50-day simple moving average of $21.09 and a two-hundred-day simple moving average of $22.23. The stock has a market capitalization of $5.76 billion, a price-earnings ratio of 48.52 and a beta of 0.32.
A number of hedge funds have recently increased or reduced their stake in SHC. Victory Capital Management Inc. increased its holdings of Sotera Health shares by 370.9% during the 4th quarter. Victory Capital Management Inc. now owns 2,514,525 shares of the company valued at $59,217,000 after purchasing an additional 1,980,563 shares in the last quarter. Schroder Investment Management Group increased its holdings of Sotera Health shares by 134.5% during the 4th quarter. Schroder Investment Management Group now owns 1,959,946 shares of the company valued at $46,157,000 after purchasing an additional 1,124,162 shares in the last quarter. Point72 Asset Management LP purchased a new stake in Sotera Health stock during Q4, valued at approximately $15,770,000. BlackRock Inc. increased its holdings of Sotera Health shares by 6.6% during the third quarter. BlackRock Inc. now owns 10,791,483 shares of the company valued at $282,196,000 after purchasing an additional 664,248 shares in the last quarter. Finally, Stockbridge Partners LLC increased its equity stake in Sotera Health by 5.7% during the third quarter. Stockbridge Partners LLC now owns 9,937,488 shares of the company valued at $259,865,000 after purchasing an additional 532,903 shares in the last quarter. 87.13% of the shares are currently held by hedge funds and other institutional investors.
About Sotera Health (Get a rating)
Sotera Health Company provides sterilization, laboratory testing and consulting services in the United States, Canada, Europe and worldwide. The Company’s sterilization services include gamma and electron beam irradiation and EO processing; Nelson Labs includes microbiological and analytical chemistry testing; and consulting services for the medical device and biopharmaceutical industries.
Get a Free Copy of Zacks’ Research Report on Sotera Health (SHC)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Sotera Health right now?
Before you consider Sotera Health, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Sotera Health wasn’t on the list.
Although Sotera Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here